July / August 2020 • PharmaTimes Magazine • 4-5

Contents

Analysis

Experts at Wilmington Healthcare explore how patients are increasingly being empowered to manage their conditions at home

Which biomolecule will reign supreme for biomarker discovery?

The challenges of competition law for pharma and recent CMA decisions

Kulveer Singh looks at what’s needed to support a new patient-centric cancer care ecosystem

Features

John Pinching on diversity in pharma and healthcare

Stephen Frost considers whether pharma is too introspective to be truly inclusive

How 3D bioprinting is pushing the bounds of human tissue engineering

Defining the gaps in antibiotic pandemic preparedess

COVID-19 and the future of healthcare

SmartPeople

PharmaTimes talks to Demetrius Carter, SVP of Regulatory Operations / Services at Certara about the reality of diversity and inclusion in their companies  

PharmaTimes talks to Kim Innes, Teva's General Manager UK & Ireland about the reality of diversity and inclusion in their companies

Melissa Baxter on the difficulties she experienced jumping from academia into an MSL role